The VLA4 (CD49d/CD29) integrin is a cell surface receptor involved in the interaction of lymphoid cells with both extracellular matrix (ECM) and endothelial cells. We have investigated the expression and function of VLA4 fibronectin (FN) receptors on T cells localized in the inflammed synovium of patients with rheumatoid arthritis (RA). A high proportion of T cells in both synovial membrane (SM) and synovial fluid (SF) expressed the activation antigens AIM (CD69) and gp95/85 (Ea2) as well as an increased number of VLA4a and fil adhesion molecules, as compared with peripheral blood (PB) T cells from the same patients. Furthermore, the majority of these activated SF T cells were able to adhere to a 38-kD FN proteolytic fragment containing the connecting segment-i (CS-i) specifically through VLA4 receptors, whereas a significantly lower proportion of PB T cells displayed this capacity. Therefore, our results show that activated T cells selectively localize at sites of tissue injury in RA disease and provide evidence for the in vivo regulation of the expression and function of the VLA4 integrin. This regulatory mechanism may enable T cells either to facilitate migration or to persist at sites of inflammation. (J. Clin. Invest. 1991. 88:546-552.)
Introduction
The integrin family includes receptors for extracellular matrix (ECM)1 components as well as receptors involved in cell-cell adhesive interactions (1) (2) (3) . The ,31 integrin subfamily, also known as very late activation antigen (VLA) proteins contains at least six different a chains (VLA-I -VLA-6) associated with a common # chain that function as receptors for ECM proteins such as collagen, fibronectin, and laminin (reviewed in reference 4). Recently, novel associations of a and # subunits have 1 . Abbreviations used in this paper: AIM, activation inducer molecule; CS-I, connecting segment 1; ECM, extracellular matrix; FN, fibronectin; PB, peripheral blood; RA, rheumatoid arthritis; SF, synovial fluid; SM, synovial membrane; VCAM-1, vascular cell adhesion molecule; VLA, very late activation antigen.
been found, which expand the molecular and functional repertoire of VLA integrins (4) .
VLA-4 is a member of the #31 integrins that is expressed by resting lymphocytes, monocytes, as well as by most T and B cell lines (4) (5) (6) (7) . Unlike other VLA members, the VLA-4 heterodimer has been implicated in cell-cell adhesion and antibodies against human VLAa4 chain inhibit the attachment oflymphocytes to high endothelial venule cells from Peyer's patches (8, 9) . A VLA-4 ligand in activated endothelial cells has been recently discovered, vascular cell adhesion molecule (VCAM-1), that belongs to the Ig gene superfamily (10, 11) . In addition, VLA-4 plays a role in both heterotypic adhesion between cytolytic T lymphocytes and B cell targets (12, 13) , and homotypic leukocyte aggregations triggered by anti-VLAa4 antibodies (14, 15) .
Similarly to the rest of VLA proteins, VLA-4 has also been involved in cell-ECM protein interactions. Thus, has been demonstrated to bind, in a RGD-independent manner, to the connecting segment 1 (CS-1) offibronectin in both T and B cell lines (10, 16, 17) . Recent studies indicated that the expression of three different VLA heterodimers (VLA-4, VLA-5, and VLA-6) is regulated during T cell maturation, because higher amounts ofthese integrins are found on memory (CD45RO+) T cells as compared with naive (CD45RO-) T cells (18).
As described for the LFA-l leukocyte integrin (19) , the constitutive expression of VLA receptors does not necessarily imply that they are functionally active. Thus, it has been described that the in vitro activation of CD4+ T cells by phorbol esters and other stimuli induces VLA-mediated attachment to ECM proteins (18, 20) .
We have addressed the question whether a regulated expression and function ofthe VLA4 fibronectin receptors exists on T cells which are activated in vivo in a pathological situation. Rheumatoid arthritis (RA) constitutes a human model of chronic articular inflammatory disease, where T cells infiltrating the synovium may play an important role in the pathogenesis of this disease (21) . The activation state of T lymphocytes can be investigated by means of the expression of activation molecules on the lymphocyte surface. It is well known that synovial fluid (SF) T cells are activated, because they express HLA-DR and VLA-1 antigens, although they lack expression of IL-2 and transferrin receptor molecules (22) (23) (24) (25) .
In this study, we have more precisely determined the activation state of SF T cells by studying the expression oftwo novel lymphocyte activation antigens: AIM (CD69), the earliest inducible molecule on T cells, which is functionally associated to the proliferative process ofT cells (26) , and gp95/85, an activation molecule similar in cell distribution and molecular characteristics to the previously described Ea2 activation antigen (27 Monoclonal antibodies (mAb). The mAb directed against activation molecules in these studies were as follows: TPI/55 (anti-AIM/CD69) (26) and TPI/16 (anti-gp95/85), whose characterization will be described in detail elsewhere. Two different mAb were used to study the VLA complex: TS2/16, which recognizes the VLA B I subunit (29) , and HP2/1 directed towards the VLA-4a4 subunit (6, 14) . The UCHL1 anti-CD45RO was kindly provided by Dr. P. C. Beverley (Imperial Cancer Research Foundation, London, UK).
The mAb used to assess the purity ofT cell preparations were SPVT3b (anti-CD3) (30), Bear-l (anti-CDI lb) (31) , and BC-l (anti-CD20) (32) . Anti-Mo-2 (CD14) was kindly provided by Dr. J. E. de Vries (Unicet Labs, Dardilly, France). Other mAb used as control was D3/9 mAb specific for the leukocyte common antigen (T200/CD45) (33 (34) . Briefly, 4 gm acetone fixed sections were sequentially incubated with mAb culture supernatants and peroxidaseconjugated rabbit anti-mouse Ig (Dakopatts, Cophenhagen, Denmark); each incubation was followed by three washes. The reaction was developed with Graham-Karnovsky medium containing 0.5 mg/ml of 3-3 diaminobenzidinetetrahydrochloride and hydrogen peroxide. Sections were counterstained with Carazi's hematoxilin followed by dehydration and mounting by routine methods.
Cell attachment analysis. Human fibronectin 38 kD proteolytic fragment (from Dr. Garcia-Pardo, Columbia University, New York) and type I collagen (Sigma Chemical Co., St. Louis, MO) were applied to 96-well flat bottom microtiter plates (Linbro; Flow Laboratories, Inc.) (40 ug/ml, 0.1 ml/well) in CO3HNa 0.1 M at 4°C overnight. Unbound binding sites were satured with RPMI 1640-1 % human seroalbumin for 2 h at 37°C. Purified T cells isolated from peripheral blood and synovial fluid were added (125,000 cells/well) in 0. 
Results
Previous studies have described the existence ofsubsets ofactivated T cells bearing the MHC class II and VLA-1 antigens infiltrating the synovium ofpatients with RA (22) (23) (24) . We have determined more precisely the activation state ofT cells in both SF and peripheral blood (PB) compartments by studying the expression of two novel activation antigens AIM (CD69) and gp95/85 (Ea2). A remarkable high expression of both activation molecules was observed in SF T cells as compared to the weak expression ofAIM and gp95/85 by PB T cells from same patients (Table I and Fig. 1 ). The expression of both AIM and Fig. 1 ). Levels ofVLA4 expression on PB T cells from patients with RA were in the same range than those displayed by PB T cells from healthy donors (Table I) . However, no significant changes in the expression levels of other cell surface antigens such as CD3 or CD45 were observed between SF and PB T cells (data not shown).
Similarly to SF T cells, the infiltrating CD3+ T lymphocytes located in the SM of RA patients (data not shown), also expressed the VLA-4 integrin and the CD69 activation antigen, as assessed by immunoperoxidase staining of synovial membrane (SM) tissue sections (Fig. 2) . Most of the VLA-4+ T cell aggregates infiltrating SM were in the perivascular space although some scattered VLA-4+ T cells were also observed all over SM. The majority of the AIM+ T cells in SM also coexpressed the VLA-4 antigen as demonstrated by double immunostaining with anti-AIM and anti-VLA-4 mAb. Similar results were obtained with the anti-gp95/85 mAb (data not shown).
To determine the functional capacity of VLA-4 receptors expressed by these cells, adhesion studies to the 38-kD FN fragment were performed with T cells purified from both PB and SF compartments of RA patients. The majority (79%) of SF T cells were capable to adhere to plastic plates coated with the 38 kD FN fragment, whereas only a reduced percentage (30%) of PB T cells displayed this capacity (Figs. 3 and 4) . The percentages of PB T cells in RA patients that bound to 38 kD FN were in the same range to those found in PB T cells from healthy donors and correlated with the percents of lymphocytes bearing the CD45RO T cell memory marker (Fig. 3 , and data not shown). Neither SF nor PB T cells bound to plates coated with collagen because they did not express detectable amounts of the VLA-2 collagen receptor (data not shown). Percentages of cell binding both in SF and PB correlated with the fractions of cells bearing the activation antigen gp95/85 and the CD45RO marker (Fig. 3) .
The attachment of T cells from both PB and SF to the 38 kD FN fragment is illustrated in Fig. 4 , A and C, respectively. T cell binding to this ECM component was specifically mediated through VLA-4 receptors because the anti-VLAa4 HP2/1 (22, 25) . Furthermore, a subset of T cells in the SF displays a low expression of the VLA-lI activation antigen, a member of the VLA integrin adhesion family, although they lack expression of IL-2 and transferrin receptor molecules (23) (24) (25) . However, both HLA-DR and VLA-l are not the more appropriate antigen markers to assess activation of T cells because they are also expressed by a wide variety of cell types at both resting and activated states (4, 35) . (37) .
The percentages of RA PB T cells displaying functional capacity to adhere to 38-kl) FN are within the same range of those previously described in PB T cells from healthy donors and correspond to the CD45RO+ memory T cell subset (18). The CD45RO+ PB T cells have been reported to express higher amounts of different adhesion receptor molecules than the CD45RO-naive T cells (38) , correlating with their enhanced functional adhesive capacity to ECM protein components (18).
We have also found that most ofactivated T cells in SF bear the CD45RO marker as described by other authors (39) , and in agreement with in vitro studies showing the acquisition of CD45RO antigen upon T cell activation (38, 40) .
The VLA-4 integrin plays a dual role as a receptor involved in both cell-cell and cell-ECM adhesive interactions through the two known ligands VCAM-lI and FN. Our data reveal that activated T ble ofthese putative conformational changes still remains to be elucidated. It has been proposed that phosphorylation of specific residues plays a role in the regulation of the functional states of integrin molecules (46, 47) .
The functional significance of the presence of in vivo activated T cells bearing functionally active VLA-4 FN receptors locally infiltrating inflamed synovium of RA patients remains uncertain. It is tempting to speculate about a role of VLA-4 in the pathogenesis ofRA. Thus, it could be suggested that VLA-4 may direct the migration of these cells to sites ofinflammation where a high concentration of fibronectin exists. In this sense, fibronectin has been detected in higher levels in SF from patients with RA than in plasma and other SF (48, 49) . Rised levels of FN in SF from rheumatoid joints may be possibly accounted for a restricted and localized increase in the production of this protein by synovial cells at the site of the articular disease. It is therefore possible that the local production of FN within affected joints may influence the continuance of arthritis depending on the amounts synthesized by the stimulated synovial tissue (50, 51) . Conceivably, these T cells have undergone an antigen-dependent activation process as deduced from their activated phenotype and have a increased number of functional FN receptors that facilitate their migration through synovial tissue towards gradients of higher fibronectin concentration. Alternatively, the adherence of cells to FN through VLA receptors could represent a mechanism of persistency of T cells at sites of inflammation. Whether a similar regulatory mechanism in operating in other VLA receptors also expressed by T cells such as VLA-5 and VLA-6 and its possible role in the RA pathogenesis remains to be elucidated.
The VLA-4 molecule may play an additional role in lymphocyte-endothelial cell interactions through its ligand VCAM-1, (10, 52) . The relevance of VLA-4 in the lymphocyte entry to the inflammed synovium still remains undetermined. In the early stages of RA, coincident with the neovascularization ofthe SM, circulating lymphocytes adhere to endothelium in postcapillary synovial venules. T cells bearing CD45RO marker have been reported to adhere better to endothelial cells than CD45RO-cells (53) and thus, gain access more easily to the synovial membrane (54) . Further studies are required to determine whether a functional regulation ofVLA-4/VCAM-I interaction may exist on SF T cells, expressing the CD45RO marker, in a similar fashion to that here described for VLA-4/ FN. Cell binding assays ofboth SF and PB T cells from patients with RA to VCAM-1 transfectant cells as well as to endothelial cells from RA synovial tissue will be required to ascertain the role of 
